Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 223   

Articles published

SNY 51.68 -0.46 (-0.88%)
price chart
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Top Stories: Papa Murphy's Holdings, Inc. (NASDAQ:FRSH), Vince Holding ...  Stock Transcript
Why Sanofi SA (ADR) Doesn't Consider Acquisitions Essential For Future Growth
The French pharmaceutical giant, Sanofi SA (ADR) (NYSE:SNY), after considering various acquisition options, has reached the conclusion that takeovers and various deal-making opportunities would not be the most essential growth driver for the company in ...
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
Home > GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR): Are Big Pharma Stocks In Trouble?
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
VBI Vaccines Inc. (VBIV) Shares Soar After Partnership With Sanofi SA (ADR)
VBI Vaccines Inc. (NASDAQ:VBIV) jumped more than 20% in after-hours trade on Monday, following an announcement that the vaccines division of Sanofi SA (ADR) (NYSE:SNY), Sanofi Pasteur, will apply VBI's LPV� (Lipid Particle Vaccine) formulation ...
Sanofi SA (ADR): Differing Regulatory Decisions Harm Global Drug Research
The marked difference in the timings of regulatory decisions worldwide regarding new medicines is a pressing issue affecting the profitability of pharmaceutical research, as discussed by Elias Zerhouni, head of research at Sanofi SA (ADR) (NYSE:SNY) on ...
Sanofi SA (ADR), Evotec Enter Into �250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth �250 million.
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ...  NYSE Post
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin  Bidness ETC
Sanofi Wins Approval For New Insulin Drug  Nasdaq